Merck & Co., Inc. (MRK): Marketing Mix Analysis [June-2026 Updated]

This ready-made analysis gives you a clear, research-based view of Merck & Co., Inc. Business as of late 2025, showing how its portfolio is built around Keytruda, Gardasil 9, Winrevair, Capvaxive, and a late-stage pipeline in oncology, hematology, and virology; how it reaches customers across 140+ countries and 5 reporting regions under the MSD name outside the U.S. and Canada; how ASCO, ACC, FDA and EU filings, plus partnerships with Moderna, Mayo Clinic, and NVIDIA support promotion; and how premium pricing, the Januvia IRA discount, and generic and biosimilar pressure shape margins and market position.

Merck & Co., Inc. - Marketing Mix: Product

Merck & Co., Inc. was still highly concentrated in Keytruda and Gardasil/Gardasil 9, which together generated $33.9B in 2023, or 56.4% of total revenue of $60.1B. Winrevair and Capvaxive are the newest commercial products, and they matter because they widen the portfolio beyond oncology and vaccines.

Keytruda is pembrolizumab, an anti-PD-1 monoclonal antibody sold as a 100 mg/4 mL intravenous concentrate. Adult dosing includes 200 mg every 3 weeks and 400 mg every 6 weeks. The product matters because it gives Merck & Co., Inc. a large, diversified cancer franchise rather than a single-tumor therapy.

Keytruda also sets the revenue base for the product mix. A single product at $25.0B in annual sales gives Merck & Co., Inc. strong scale, but it also creates concentration risk, which is why new launches and pipeline assets matter for the marketing mix.

Gardasil and Gardasil 9 are the vaccine anchor. Merck & Co., Inc. reported $8.9B in 2023 sales for the franchise. Gardasil 9 protects against 9 HPV types, and the U.S. product is used in ages 9 to 45. The main presentation is a 0.5 mL intramuscular dose.

Gardasil 9 matters because it is preventive, not therapeutic. That gives Merck & Co., Inc. a product with long-duration public health demand and a different customer base from oncology, which helps smooth the company’s product mix.

Winrevair is the newest major franchise in pulmonary arterial hypertension. It received U.S. approval on March 26, 2024, for adults with PAH. The labeled regimen starts at 0.3 mg/kg and moves to 0.7 mg/kg every 3 weeks. It expands Merck & Co., Inc. beyond cancer and vaccines into chronic specialty care.

Capvaxive broadened the adult vaccine portfolio in 2024. It is a 21-valent pneumococcal conjugate vaccine approved for adults 18 years and older. The dose is 0.5 mL intramuscularly. This product gives Merck & Co., Inc. another preventive-care asset with a different clinical use than Gardasil 9.

• Keytruda sales: $25.0B in 2023
• Gardasil/Gardasil 9 sales: $8.9B in 2023
• Keytruda plus Gardasil/Gardasil 9: $33.9B in 2023
• Combined share of Merck & Co., Inc. revenue: 56.4%
• Other products and business lines: $26.2B in 2023

Late-stage pipeline still spans oncology, hematology, and virology. Oncology is the clearest expansion area, with sacituzumab tirumotecan in phase 3 development. Virology includes clesrovimab, Merck & Co., Inc.'s long-acting RSV antibody program. Hematology remains part of the broader development base and supports future diversification away from the current concentration in Keytruda and Gardasil.

• Oncology: sacituzumab tirumotecan in phase 3 development
• Virology: clesrovimab in late-stage development for RSV prevention
• Hematology: late-stage blood-disease programs in development

Merck & Co., Inc. - Marketing Mix: Place

Merck & Co., Inc. operates in more than 140 countries and uses the MSD name outside the U.S. and Canada. Its place strategy is built around regulated, high-control channels because much of its portfolio is prescription, vaccine, or Animal Health product that cannot move through ordinary retail distribution.

Merck reports sales across 5 regions: United States and Canada, Europe, China, Japan, and Rest of World. That structure matters because it shows how the company organizes market access, logistics, and demand planning by geography instead of using a single global sales channel.

The global supply chain supports both human health and Animal Health, so Merck has to manage multiple delivery models in one network. That means inventory planning, temperature control, and shipment timing matter for vaccines and biologics, where product availability affects hospitals, clinics, pharmacies, veterinarians, and government buyers.

• More than 140 countries of operation
• 5 geographic sales regions
• MSD name outside the U.S. and Canada
• Human health and Animal Health use the same global supply chain
• Vaccine distribution depends on regional manufacturing and cold-chain logistics

Regionalizing vaccine manufacturing helps Merck align production with demand in major markets, shorten lead times, and reduce dependence on long cross-border shipments. For vaccines, place is not only where a product is sold; it is also where it is made, packed, released, and moved into local distribution channels.

Merck & Co., Inc. - Marketing Mix: Promotion

As of late 2025, Merck & Co., Inc. promotes through clinical evidence, congress visibility, regulatory milestones, and access programs. The company’s promotion is built for specialists, payers, and health systems, so trial data and approvals matter more than mass advertising.

Heavy clinical-trial and congress readouts: Merck uses Phase 2 and Phase 3 data as the core of its promotion because each readout can extend a product’s life cycle and keep the brand in medical discussion. For oncology, ASCO is a major stage. For cardiology and cardiopulmonary disease, ACC serves the same role. That matters commercially because Keytruda generated $29.5 billion in 2024 sales.

ASCO and ACC presentations support launches: At ASCO, Merck keeps oncology assets in front of oncologists with efficacy, safety, and follow-up data. At ACC, the company keeps cardiopulmonary data in front of specialists who influence hospital adoption and formulary review. These meetings matter because they turn product claims into peer-reviewed discussion and conference coverage.

FDA and EU filings build awareness: Merck uses regulatory milestones as promotion because filings, reviews, and approvals create news flow for physicians and payers. The 2024 FDA approvals of Winrevair and Capvaxive gave the company two launch moments tied directly to scientific evidence and label expansion. EU filings serve the same purpose by widening the market conversation beyond the U.S.

Partnerships with Moderna, Mayo Clinic, NVIDIA: The Moderna collaboration is the clearest promotional example because it ties Merck to personalized cancer vaccine research and a 157-patient Phase 2b readout. Mayo Clinic adds academic credibility in physician-facing communication, and NVIDIA adds AI credibility in discovery messaging. Those partnerships matter because they make Merck’s promotion look like clinical science, not advertising.

Purpose for Progress emphasizes access: Access is part of Merck’s public promotion, not a separate message. The MECTIZAN Donation Program started in 1987 and has donated more than 4 billion tablets. That scale gives Merck a long-running public-health story that supports trust with governments, NGOs, and global health buyers.

• ASCO keeps oncology data visible to specialists who prescribe Keytruda.
• ACC keeps cardiopulmonary data visible to specialists who may adopt Winrevair.
• FDA approvals in 2024 turn trial data into launch-stage awareness.
• Moderna, Mayo Clinic, and NVIDIA partnerships add third-party credibility to Merck’s scientific message.
• Capvaxive is a 21-valent pneumococcal vaccine, and Gardasil 9 is a 9-valent HPV vaccine.
• The MECTIZAN Donation Program links promotion to access with 1987 and more than 4 billion tablets donated.

Merck & Co., Inc. - Marketing Mix: Price

Merck’s price power sits mainly in patent-protected brands: $25.0B from Keytruda and $8.9B from Gardasil/Gardasil 9 in 2023, or $33.9B combined out of $60.1B total revenue.

Premium pricing on patent-protected brands

Keytruda represented 41.6% of Merck’s $60.1B 2023 revenue. Gardasil/Gardasil 9 represented 14.8%.

• Keytruda: $25.0B in 2023 sales
• Gardasil/Gardasil 9: $8.9B in 2023 sales
• Combined: $33.9B in 2023 sales
• Share of Merck 2023 revenue: 56.4%

Biologics and specialty drugs sustain margins

The main high-price drivers are the same two products: $25.0B Keytruda and $8.9B Gardasil/Gardasil 9. Their combined $33.9B sales in 2023 left $26.2B of Merck revenue from the rest of the portfolio.

• $33.9B combined sales from Keytruda and Gardasil/Gardasil 9
• $26.2B revenue from all other Merck products in 2023
• 56.4% of 2023 revenue from two products

Januvia faces IRA negotiated-price discount

Januvia’s Medicare negotiated price is $113.00 per 30-day supply, effective 2026, with a 79% discount from the list price.

• Effective date: 2026
• Negotiated price: $113.00 per 30-day supply
• Discount: 79%

Generic and biosimilar entry may compress prices

Generic sitagliptin entered the U.S. market in 2023. That kind of entry is the clearest price pressure point on Merck’s oral diabetes franchise.

• U.S. generic sitagliptin entry: 2023
• Januvia Medicare negotiated price: $113.00
• Negotiated discount: 79%